Completed

Gastric Volume in Patients on GLP-1 Medications

Lead sponsor

Children's Hospital of Philadelphia

Asset

GLP-1 / incretin class catch-all

Listed sites

Recruiting sites

Actual enrollment

Study population

Obesity / overweight

Eligibility highlights

Primary endpoint

•Gastric volume in pediatric patients on GLP-1 RA

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT05903482

Org study ID23-021125

Timeline

Milestones

Study start2023-06-06actual

Study first posted2023-06-15actual

Primary completion2024-12-31actual

Study completion2024-12-31actual

Last update posted2025-03-19actual

Assets

Investigational agents

GLP-1 / incretin class catch-all

Who this study enrolls

Obesity / overweight

Who can enroll

Maximum age18 Years

SexAll

Healthy volunteersNot accepted

Sampling methodProbability sample

Study population text

Fasting children on GLP-1 RA

Inclusion criteria

Fasting Diabetic On GLP-1 RA

Exclusion criteria

Prior surgery that affects gastric anatomy

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Other (unclassified)

1 endpoint

Primary/protocol endpoint/low confidence

Gastric volume in pediatric patients on GLP-1 RA

Time frame:Day 1

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.